• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medical devices drive Covidien’s Q3 surge

Medical devices drive Covidien’s Q3 surge

July 26, 2011 By MassDevice staff

Covidien

Shares of Covidien plc (NYSE:COV) rose more than 4 percent this morning after the company announced a third-quarter profit bump of 47.0 percent and a top-line boost of 14.1 percent.

Wall Street liked the 22 percent sales boost added by the Mansfield, Mass.-based health products maker’s workhorse medical device segment during the three months ended June 24, which powered the surge. Even better, Covidien bested both its own forecast and The Street’s expectations.

“We delivered another strong quarter, and, for the fourth quarter in a row, results significantly exceeded our own expectations,” president & CEO Joe Almeida said in prepared remarks. “These results were spurred by the performance of our largest business segment, medical devices, which again reported substantial growth that was led by excellent increases for vascular and energy products. We continued to benefit from several successful new product launches and from market share gains in an increasingly competitive global healthcare marketplace.”

Covidien reported profits of $535 million, or $1.07 per diluted share, on sales of $2.93 billion for the three months ended June 24. That’s compared with net income of $364 million, or 72 cents diluted EPS, on sales of $2.56 billion during the same period last year.

Excluding one-time items, adjusted diluted EPS was $1.01 for the quarter — analysts had expected earnings of 95 cents per share (with a high estimate of 97 cents), according to MarketWatch.

The medical device division, which accounted for 68 percent of total revenues during the quarter, reported sales of $1.99 billion, up from $1.63 billion during Q3 2010. Acquisitions, new products and higher sales volumes drove the growth, the company said. Sales in the U.S. were up 28 percent for the division to $874 million; overseas sales of $1.11 billion were up 18 percent.

Covidien’s pharmaceutical division posted a sales decline of 1 percent to $500 million, largely due to the sale of its U.S. radiopharmacy business last year and lower sales for its specialty pharma unit.

The medical supplies operation posted Q3 sales of $441 million, up 3 percent, paced by higher sales of med-surg and nursing care products.

Check out the exclusive MassDevice Big 100 Roundtable interview with Covidien’s Joe Almeida

The company said it bought back nearly 5 million shares of its own stock during the quarter.

“In the last 12 months, we have returned over $1 billion in cash to shareholders through dividends and share buybacks, representing more than 50 percent of our free cash flow,” Almeida noted. “Our overall Company performance remains on plan, and we are confident we will have a strong finish to the fiscal year.”

Covidien also said it expects the restructuring plan it launched during the quarter to subtract about $275 million pre-tax by the end of fiscal 2014. The changes are aimed at saving up to $225 million a year, according to the company.

COV shares were trading at $52.30 in mid-day activity, up 4.1 percent.

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: Covidien, Q2

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy